Administration of anti–SARS-CoV-2 monoclonal antibodies after US Food and Drug Administration deauthorization
In 2021, the US Food and Drug Administration (FDA) issued emergency use authorizations
for 2 anti–SARS-CoV-2 monoclonal antibodies (mAbs), bamlanivimab-etesevimab and
casirivimabimdevimab, to treat mild to moderate COVID-19 in high-risk ambulatory patients.
The Omicron variant was determined to not be susceptible to these treatments, leading the
FDA to deauthorize their use on January 24, 2022. 1 Given public controversy over this
decision, 2 we evaluated the administration of bamlanivimab-etesevimab and casirivimab …
for 2 anti–SARS-CoV-2 monoclonal antibodies (mAbs), bamlanivimab-etesevimab and
casirivimabimdevimab, to treat mild to moderate COVID-19 in high-risk ambulatory patients.
The Omicron variant was determined to not be susceptible to these treatments, leading the
FDA to deauthorize their use on January 24, 2022. 1 Given public controversy over this
decision, 2 we evaluated the administration of bamlanivimab-etesevimab and casirivimab …